原发性肝癌141例灌注化疗及栓塞治疗疗效分析

Efficacy analysis of transcatheter arterial infusion chemotherapy and transcatheter arterial enbolization in 141 patients with primary hepatocellular carcinoma

目的分析影响肝动脉灌注化疗+栓塞治疗疗效的因素。方法2001年5月～2006年5月,对141例不能切除的中晚期原发性肝癌行选择性插管灌注化疗及栓塞治疗。结果1、2、3、4年生存率分别为57.4%、31.9%、8.5%和1.4%,疗效较治疗初期有显著提高。其中1例存活53月以上。结论肝动脉栓塞化疗是治疗中晚期不能切除原发性肝癌患者的有效治疗方法,可以延长生存期。肿瘤的类型、临床分期、门脉癌栓、肝功能分级是影响疗效的主要因素。

Objective To analyse the factors influencing efficacy of transcatheter arterial infusion chemotherapy（TAI） and transcatheter arterial embolization （TAE）. Methods From May 2001 to May 2006,141 patients for unresectable primary hepatocellular carcinoma （HCC） were treated with transcatheter arterial infusion chemotherapy （TAI） and transcatheter arterial embolization （TAE）. The survival time of a patient were more than 53 months. Results The 1-,2-,3-,4-year survival rate was 57.4% ,31.9% ,8.5% andl.4%,respectively. Conclusion TAI and TAE were effective treatment for the patients with unresectable primary hepatocellular carcinoma （HCC） ,and may prolong the survival time. The type of carcinoma, the clinical stage of the disease, the cancer embolus of portal vein,the classification of liver function are the main factors affecting treatment effi, cacy.